Evidence map›Paper›PMID 26501144›Full record

ArticlePloS one2015

META-GSA: Combining Findings from Gene-Set Analyses across Several Genome-Wide Association Studies.

Albert Rosenberger, Stefanie Friedrichs, Christopher I Amos, Paul Brennan, Gordon Fehringer, Joachim Heinrich, Rayjean J Hung, Thomas Muley, Martina Müller-Nurasyid, Angela Risch and 1 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Albert RosenbergerDepartment of Genetic Epidemiology, University Medical Center, Georg-August University Göttingen, Göttingen, Germany.
Stefanie FriedrichsDepartment of Genetic Epidemiology, University Medical Center, Georg-August University Göttingen, Göttingen, Germany.
Christopher I AmosGeisel School of Medicine, Dartmouth College, Lebanon, NH, United States of America.
Paul BrennanInternational Agency for Research on Cancer (IARC), Lyon, France.
Gordon FehringerProsserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Joachim HeinrichInstitute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Rayjean J HungProsserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Thomas MuleyTranslational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Thoraxklinik at University of Heidelberg, Heidelberg, Germany.
Martina Müller-NurasyidDepartment of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany; Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-University, Munich, Germany; Institute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Angela RischTranslational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany; Division of Molecular Biology, University Salzburg, Salzburg, Austria.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August University Göttingen, Göttingen, Germany.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Transdisciplinary Research in Cancer of the Lung (TRICL)U19CA148127 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I., LE MARCHAND, LOIC · 2010 to 2014
$10.9M
Inflammation Genes and Lung Cancer RiskR01CA127219 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SPITZ, MARGARET R · 2008 to 2013
$3.1M
High Density Association Analysis of Lung CancerR01CA121197 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I. · 2007 to 2010
$3.0M
NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA70907NCI NIH HHS R01 CA121197NCI NIH HHS R01CA121197NCI NIH HHS R01 CA127219NCI NIH HHS U19 CA148127NCI NIH HHS U19CA148127NHGRI NIH HHS HHSN268200782096CWorld Health Organization 001
6 · The paper itself

Abstract

introductionGene-set analysis (GSA) methods are used as complementary approaches to genome-wide association studies (GWASs). The single marker association estimates of a predefined set of genes are either contrasted with those of all remaining genes or with a null non-associated background. To pool the p-values from several GSAs, it is important to take into account the concordance of the observed patterns resulting from single marker association point estimates across any given gene set. Here we propose an enhanced version of Fisher's inverse χ2-method META-GSA, however weighting each study to account for imperfect correlation between association patterns. SIMULATION AND POWER: We investigated the performance of META-GSA by simulating GWASs with 500 cases and 500 controls at 100 diallelic markers in 20 different scenarios, simulating different relative risks between 1 and 1.5 in gene sets of 10 genes. Wilcoxon's rank sum test was applied as GSA for each study. We found that META-GSA has greater power to discover truly associated gene sets than simple pooling of the p-values, by e.g. 59% versus 37%, when the true relative risk for 5 of 10 genes was assume to be 1.5. Under the null hypothesis of no difference in the true association pattern between the gene set of interest and the set of remaining genes, the results of both approaches are almost uncorrelated. We recommend not relying on p-values alone when combining the results of independent GSAs. APPLICATION: We applied META-GSA to pool the results of four case-control GWASs of lung cancer risk (Central European Study and Toronto/Lunenfeld-Tanenbaum Research Institute Study; German Lung Cancer Study and MD Anderson Cancer Center Study), which had already been analyzed separately with four different GSA methods (EASE; SLAT, mSUMSTAT and GenGen). This application revealed the pathway GO0015291 "transmembrane transporter activity" as significantly enriched with associated genes (GSA-method: EASE, p = 0.0315 corrected for multiple testing). Similar results were found for GO0015464 "acetylcholine receptor activity" but only when not corrected for multiple testing (all GSA-methods applied; p ≈ 0.02).

Indexed as

Genome-Wide Association StudyAllelesGenesGenetic MarkersGenetic Predisposition to DiseaseHumansMeta-Analysis as TopicModels, TheoreticalStatistics, NonparametricGenetic Markers

Identifiers

PMID26501144
PMCPMC4621033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.